Lu Sun

Has grant

Assistant Project Scientist

University of California
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Applying single cell and spatial transcriptomics to decipher the immunosuppressive microenvironment of brain tumors

Open Date: 2021-08-01

Close Date: 2022-07-01

Grant: Close

Overcoming adaptive immune resistance within the tumor microenvironment of primary and metastatic brain tumor patients treated with immune checkpoint blockade

Open Date: 2020-08-01

Close Date: 2021-07-01

Grant: Close

Large-scale, Single-cell Networks Driving the Evolution of Therapeutic Resistance in Melanoma

Open Date: 2019-01-01

Close Date: 2020-01-01

Articles (21)

A major obstacle to identifying effective therapies for the aggressive brain tumor glioblastoma is the lack of human-specific, immunocompetent models that reflect the human tumor microenvironment. To address this, we developed the immune-Human Organoid Tumor Transplantation (iHOTT) model. This is an autologous co-culture platform that integrates patient-derived tumor cells and matched peripheral blood mononuclear cells (PBMCs) within human cortical organoids, enabling the study of the patient-specific immune response to the tumor and tumor-immune interactions. This platform preserves tumor and immune populations, immune signaling, and cell-cell interactions observed in patient tumors. Treatment of iHOTT with pembrolizumab, a checkpoint inhibitor, mirrored cell type shifts and cell interactions observed in patients. TCR sequencing further revealed pembrolizumab-driven expansion of stem-like CD4-T-cell clonotypes exhibiting patient-specific repertoires. These findings establish iHOTT as a physiologically relevant platform for exploring autologous tumor–immune interactions and underscore the critical need for antigen-targeted strategies to enhance immunotherapy in glioblastoma.

Year:

2025

CTA induction but not downstream interferon-downstream stimulation by DAC is correlated with CpG demethylation in glioma cells. A, Heatmap and hierarchical clustering of differentially expressed CTA. Scale represents z -score of DESeq2 counts. B, Violin plot of beta value distribution between treatment conditions for CpG probes corresponding to differentially upregulated CTA ( P -value = 0.028; Wilcoxon rank sum test with continuity correction). C, Scatter plot of all CpG island probes containing intersectional DNA methylation log 2 FoldChange and RNA expression log 2 FoldChange of annotated genes in black ( n = 115,801 CpG island probes). CpG island probes corresponding to CTA with Pearson correlation are highlighted in (red; n = 535 CpG probes; n = 65 CTA genes). D, Enricher analysis of DESEQ2 differentially upregulated genes (Hallmark IFNγ P = 0.00548; Hallmark IFNα P = 0.00548; Hallmark inflammatory response P = 0.0426) and downregulated genes (Hallmark mTORC1 signaling P = 1.59e −3 ; Hallmark mitotic spindle P = 1.59e −3 , Hallmark G2M Checkpoint P = 7.77e −5 ; Hallmark E2F targets P = 7.77e −5 ). Hallmark MSigDB signature adjusted P values determined using Fisher exact test adjusted by Benjamini–Hochberg correction. E, Violin plot of beta value distribution between treatment conditions for CpG probes corresponding to differentially upregulated DAC_UP_MSigDB_Hallmark genes ( P -value = 0.497; Wilcoxon rank sum test with continuity correction). F, Scatter plot of intersectional DNA methylation log 2 FoldChange and RNA expression log 2 FoldChange CpG island probes. CpG probes corresponding to the Hallmark Interferon Alpha Response gene set with Pearson correlation are highlighted in blue ( n = 471 probes; n = 53 genes).

Year:

2025

Glioblastoma (GBM) is the most common malignant primary brain tumor and remains incurable. Previous work has shown that systemic administration of Decitabine (DAC) induces sufficient expression of cancer-testis antigens (CTA) in GBM for targeting by adoptive T-cell therapy in vivo. However, the mechanisms by which DAC enhances immunogenicity in GBM remain to be elucidated. Using New York esophageal squamous cell carcinoma 1 (NY-ESO-1) as a representative inducible CTA, we demonstrate in patient tissue, immortalized glioma cells, and primary patient-derived gliomaspheres that basal CTA expression is restricted by promoter hypermethylation in gliomas. DAC treatment of glioma cells specifically inhibits DNA methylation silencing to render NY-ESO-1 and other CTA into inducible tumor antigens at single-cell resolution. Functionally, NY-ESO-1 T-cell receptor–engineered effector cell targeting of DAC-induced antigen in primary glioma cells promotes specific and polyfunctional T-cell cytokine profiles. In addition to induction of CTA, DAC concomitantly reactivates tumor-intrinsic human endogenous retroviruses, interferon response signatures, and MHC-I. Overall, we demonstrate that DAC induces targetable tumor antigen and enhances T-cell functionality against GBM, ultimately contributing to the improvement of targeted immune therapies in glioma. Significance: This study dissects the tumor-intrinsic epigenetic and transcriptional mechanisms underlying enhanced T-cell functionality targeting decitabine-induced cancer-testis antigens in glioma. Our findings demonstrate concomitant induction of tumor antigens, reactivation of human endogenous retroviruses, and stimulation of interferon signaling as a mechanistic rationale to epigenetically prime human gliomas to immunotherapeutic targeting.

Year:

2024

In this randomized phase II clinical trial, we evaluated the effectiveness of adding the TLR agonists, poly-ICLC or resiquimod, to autologous tumor lysate-pulsed dendritic cell (ATL-DC) vaccination in patients with newly-diagnosed or recurrent WHO Grade III-IV malignant gliomas. The primary endpoints were to assess the most effective combination of vaccine and adjuvant in order to enhance the immune potency, along with safety. The combination of ATL-DC vaccination and TLR agonist was safe and found to enhance systemic immune responses, as indicated by increased interferon gene expression and changes in immune cell activation. Specifically, PD-1 expression increases on CD4+ T-cells, while CD38 and CD39 expression are reduced on CD8+ T cells, alongside an increase in monocytes. Poly-ICLC treatment amplifies the induction of interferon-induced genes in monocytes and T lymphocytes. Patients that exhibit higher interferon response gene expression demonstrate prolonged survival and delayed disease progression. These findings suggest that combining ATL-DC with poly-ICLC can induce a polarized interferon response in circulating monocytes and CD8+ T cells, which may represent an important blood biomarker for immunotherapy in this patient population.Trial Registration: ClinicalTrials.gov Identifier: NCT01204684.

Year:

2024

Year:

2024

Glioblastoma (GBM) is the most common malignant primary brain tumor and remains incurable. Previous work has shown that systemic administration of Decitabine (DAC) induces sufficient expression of cancer-testis antigens (CTA) in GBM for targeting by adoptive T-cell therapy in vivo. However, the mechanisms by which DAC enhances immunogenicity in GBM remain to be elucidated. Using New York esophageal squamous cell carcinoma 1 (NY-ESO-1) as a representative inducible CTA, we demonstrate in patient tissue, immortalized glioma cells, and primary patient-derived gliomaspheres that basal CTA expression is restricted by promoter hypermethylation in gliomas. DAC treatment of glioma cells specifically inhibits DNA methylation silencing to render NY-ESO-1 and other CTA into inducible tumor antigens at single-cell resolution. Functionally, NY-ESO-1 T-cell receptor–engineered effector cell targeting of DAC-induced antigen in primary glioma cells promotes specific and polyfunctional T-cell cytokine profiles. In addition to induction of CTA, DAC concomitantly reactivates tumor-intrinsic human endogenous retroviruses, interferon response signatures, and MHC-I. Overall, we demonstrate that DAC induces targetable tumor antigen and enhances T-cell functionality against GBM, ultimately contributing to the improvement of targeted immune therapies in glioma. Significance: This study dissects the tumor-intrinsic epigenetic and transcriptional mechanisms underlying enhanced T-cell functionality targeting decitabine-induced cancer-testis antigens in glioma. Our findings demonstrate concomitant induction of tumor antigens, reactivation of human endogenous retroviruses, and stimulation of interferon signaling as a mechanistic rationale to epigenetically prime human gliomas to immunotherapeutic targeting.

Year:

2024

DAC reactivates hERV expression in gliomaspheres. A, FPKM of ERV3 and HERVR family for primary gliomasphere cell lines ( n = 7; *, P P t test). B, Average fold change of mRNA expression of treated GS277 for ERV3 and ERVW1 /Syncytin-1 as measured by qPCR ( n = 3; *, P P t test). C, Heatmap and hierarchical clustering of hERV gene families. Scale represents z -score of hERV family FPKM normalized to housekeeping FPKM.

Year:

2024

DAC induces NY-ESO-1 and other CTA homogeneously in serum-free patient derived gliomaspheres. A, UMAP of primary gliomasphere lines (GS025, GS243) treated with DAC or DMSO ( n = 22,313; B ) UMAP of cells expressing CTAG1B (red). C, 35% ( n = 1,487 CTAG1B + cells of 4,190 DAC-treated cells) of treated cells demonstrate CTAG1B upregulation. D, UMAP and ( E ) proportion of cell populations as determined by Seurat and differentially expressed cluster markers. F, Relative gene expression of cells expressing CTAG1B and pan-MHC class 1 ( HLA- A , HLA- B , HLA- C ) in GS025_DMSO (light blue), GS025_DAC (light red), GS243_DMSO (dark blue), and GS243_DAC (dark red) across defined cell populations.

Year:

2024

DAC immunesensitization promotes specific, robust, and polyfunctional NY-ESO-1 TCR CD8 + T-cell responses in primary GBM cell lines. A, Representative Bis-Seq-TA cloning lollipop diagram and ( B ) percent of methylated CpGs to total CpGs of first eight sites of analyzed CpG island in primary GS277 cells treated with DMSO or 0.5 µmol/L DAC for 12 days. C, Average fold change of mRNA expression of treated GS277 ( n = 3; **, P t test). D, Cytotoxic analysis of treated GS277 over a 40-hour period when co-incubated with NY-ESO-1 TCR-transduced effector T cells at E:T ratio of 1:1 and ( E ) at multiple E:T ratios (1:5, 1:2, 1:1, 2:1) at 20-hour ( n = 3; *, P P P P t tests). F, Uniform manifold approximation projection (UMAP) of CD8 + T cells transduced with NY-ESO-1 TCR CD8 or untransduced control CD8 (CTR) from four stimulated groups: NY-ESO-1 CD8 + alone ( n = 1665 CD8 + cells), NY-ESO-1 CD8 + stimulated with DBTRG-05 ( n = 1902 CD8 + cells), NY-ESO-1 CD8 + stimulated with DBTRG-05 + DAC ( n = 284 CD8 + cells), CTR CD8 stimulated with DBTRG-05 + DAC ( n = 807 CD8 + cells). G and H, PSI defined as the percentage of polyfunctional cells, multiplied by MFI of the proteins secreted by the polyfunctional cells for stimulated CD8 + at the single-cell resolution across DBTRG-05 co-cultures.

Year:

2024

DAC reactivates hERV expression in gliomaspheres. A, FPKM of ERV3 and HERVR family for primary gliomasphere cell lines ( n = 7; *, P P t test). B, Average fold change of mRNA expression of treated GS277 for ERV3 and ERVW1 /Syncytin-1 as measured by qPCR ( n = 3; *, P P t test). C, Heatmap and hierarchical clustering of hERV gene families. Scale represents z -score of hERV family FPKM normalized to housekeeping FPKM.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (10)

Aparna Bhaduri

Assistant Professor

University of California, Los Angeles

UNITED STATES
View details

Linda Liau

Professor

Ronald Reagan UCLA Medical Center

UNITED STATES
View details

Anthony C. Wang

University of California, Los Angeles

UNITED STATES
View details

Won Kim

UCLA Health

UNITED STATES
View details

Shanpeng Li

Staff Scientist

Beckman Research Institute, City of Hope

UNITED STATES
View details

Willy Hugo

Associate Professor

David Geffen School of Medicine at UCLA

UNITED STATES
View details

Jeremy G. Reynoso

University of California, Los Angeles

UNITED STATES
View details

Matthew Sun

Assistant Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Richard Everson

Assistant Professor In Residence

David Geffen School of Medicine at UCLA

UNITED STATES
View details

Robert Prins

Professor (with tenure)

Ronald Reagan UCLA Medical Center

UNITED STATES
View details